BioSpace News Archive

Kallyope, Inc., a leading biotechnology company focused on identifying and developing therapeutics involving the gut-brain axis, today announced the formation of its inaugural Clinical Development Advisory Board.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that studies utilizing its portfolio of blood tests and real-world data will be presented at the IASLC 2022 World Conference on Lung Cancer (WCLC 2022), hosted by the International Association for the Study of Lung Cancer, August 6-9 in Vienna, Austria.

Tarsus Pharmaceuticals, Inc. today announced that it has enrolled the first patient in a Phase 2a clinical trial studying TP-03 (lotilaner ophthalmic solution, 0.25%) for the treatment of Meibomian Gland Disease (MGD) in patients with Demodex mites.

Delcath Systems, Inc. announced the publication of a retrospective analysis of patients who underwent a percutaneous hepatic perfusion procedure (PHP) with CHEMOSAT® at three European centers, one in the Netherlands and two in Germany, between February 2014 and December 2019.

Relmada Therapeutics, Inc. today announced that it will report its financial results for the second quarter and six months ended June 30, 2022 , after the market close on Thursday, August 11, 2022.

Legend Biotech Corporation today in conjunction with an announcement to be issued by Legend Biotech’s majority shareholder, GenScript Biotech Corporation, pursuant to the rules of The Stock Exchange of Hong Kong Limited, announced preliminary, unaudited financial results for the six-months ended June 30, 2022.

Helius Medical Technologies, Inc. today announced the pricing of a public offering of (i) 24,000,000 shares of its Class A common stock (or common stock equivalents in lieu thereof) and (ii) warrants to purchase up to 36,000,000 shares of its Class A common stock (“Public Warrants”) at a purchase price of $0.75 per share,

CASI Pharmaceuticals, Inc. today announced the Company will host a conference call reviewing the financial results for the second quarter of 2022, at 8:00 A.M. EST on Friday, August 12, 2022.

We are increasingly being exposed to endocrine-disrupting chemicals (EDCs) that interfere with the normal functioning of our hormones.

United BioPharma (UBP) today announced their latest results featuring unprecedented and unique functional characteristics of UB-221 monoclonal antibody in the phase I single-dose clinical trial, with chronic spontaneous urticaria (CSU) patients, to exhibit durable disease symptom relief.